Clinical Trial Update: Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating Iparomlimab/Tuvonralimab (QL1706) with XELOX in HER2-negative, low PD-L1 expressing unresectable or metastatic gastric/gastroesophagea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Iparomlimab (Tuvonralimab, QL1706) (Iparomlimab)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: HER2 Negative, Low PD-L1 Expressing | Phase 2 | Status: RECRUITING